ArticleJournal of contemporary brachytherapy2026
Concurrent chemoradiation and high-dose-rate brachytherapy for synchronous muscle-invasive bladder carcinoma and very high-risk prostate adenocarcinoma: A case report.
Article in Journal of contemporary brachytherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Synchronous presentation of clinically significant bladder urothelial carcinoma and prostate adenocarcinoma is rare. While prostate cancer identified at cystoprostatectomy is often incidental, truly synchronous high-risk disease presents challenges for patients pursuing organ preservation due to overlapping radiation fields and differing dose requirements. We report a case of muscle-invasive bladder cancer and NCCN very high-risk prostate adenocarcinoma successfully managed with bladder-preserving chemoradiation and high-dose-rate (HDR) brachytherapy boost. Material and methods: A 70-year-old man was diagnosed with high-grade urothelial carcinoma of the bladder, initially staged as cT1 and progressing to cT2 after repeat transurethral resections and intravesical bacillus Calmette-Guérin (BCG). Concurrent prostate adenocarcinoma was identified (Gleason 5 + 4 = 9, prostate-specific antigen [PSA] 13.59 ng/ml, clinical stage IIIC). Staging with CT urogram, CT chest, PSMA PET, and prostate MRI demonstrated no metastatic disease. Following multidisciplinary discussion, the patient elected bladder preservation with definitive prostate cancer treatment. Management included androgen deprivation therapy with goserelin and abiraterone, repeat TURBT, and pelvic chemoradiation delivering 45 Gy with a sequential external beam boost of 64.8 Gy to the bladder tumor bed, with concurrent weekly cisplatin. To achieve curative prostate dosing, single-fraction HDR brachytherapy boost of 15 Gy was delivered to the prostate and proximal seminal vesicles using a transperineal, image-guided, template-based technique. Organ at risk constraints included bladder D Results: At 24 months post-treatment, the patient remains disease-free with no grade ≥ 3 toxicities. PSA declined to < 0.01 ng/ml by 12 months and remains suppressed. Late effects included stable mild right hydronephrosis, grade 2 nocturia, and grade 1 fatigue. Conclusions: HDR brachytherapy boost following pelvic chemoradiation is a feasible strategy for synchronous muscle-invasive bladder and very high-risk prostate cancer, enabling prostate dose escalation while respecting bladder tolerance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.